Author | Lisa Astor


VERU-111 Shows Early Promise and Safety in mCRPC After Progression on AR Therapy

October 22, 2020

A novel tubulin inhibitor VERU-111 has demonstrated promising early antitumor activity and tolerability in men with metastatic castration-resistant prostate cancer who have failed prior androgen receptor therapy, according to the results of a phase 1b/2 study.

The Battle for the Front Line in CLL Moves Away From Chemoimmunotherapy

October 14, 2020

Traditional frontline chemoimmunotherapy regimens used to be the gold standard for treating patients with newly diagnosed chronic lymphocytic leukemia. However, over time, targeted therapies have been inching out the use of chemoimmunotherapy to become the preferred approach in this setting.